Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer

Lantern Pharma Inc. (LTRN)

We couldn't retrieve the full text for this release. Read it on the company's site.